Literature DB >> 17762780

Mosquito stage, transmission blocking vaccines for malaria.

Allan Saul1.   

Abstract

PURPOSE OF REVIEW: This review highlights progress made in the development of vaccines aimed at the stages of malaria parasites found in mosquitoes that block the transmission of malaria within a community. RECENT
FINDINGS: Substantial progress has been made on the production and characterization of the leading candidates P25 and P28 from Plasmodium falciparum and P. vivax. Immunogenicity data have been obtained for P25 in humans that showed significant transmission blocking activity and further advances in formulation should boost this activity. The completion of the malaria genome and ongoing proteomics identified further candidate antigens now entering development.
SUMMARY: Recent advances increase confidence that a mosquito stage transmission blocking malaria vaccine will be feasible.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17762780     DOI: 10.1097/QCO.0b013e3282a95e12

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  34 in total

1.  In vitro generation of Plasmodium falciparum ookinetes.

Authors:  Viengngeun Bounkeua; Fengwu Li; Joseph M Vinetz
Journal:  Am J Trop Med Hyg       Date:  2010-12       Impact factor: 2.345

2.  Lack of molecular correlates of Plasmodium vivax ookinete development.

Authors:  Viengngeun Bounkeua; Fengwu Li; Raul Chuquiyauri; Shira R Abeles; Colleen M McClean; Victor Neyra; Alejandro Llanos-Cuentas; Pablo P Yori; Joseph M Vinetz
Journal:  Am J Trop Med Hyg       Date:  2011-08       Impact factor: 2.345

Review 3.  Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination.

Authors:  Teun Bousema; Chris Drakeley
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

4.  Mosquito ingestion of antibodies against mosquito midgut microbiota improves conversion of ookinetes to oocysts for Plasmodium falciparum, but not P. yoelii.

Authors:  Bruce H Noden; Jefferson A Vaughan; Charles B Pumpuni; John C Beier
Journal:  Parasitol Int       Date:  2011-07-13       Impact factor: 2.230

Review 5.  Immune mechanisms in malaria: new insights in vaccine development.

Authors:  Eleanor M Riley; V Ann Stewart
Journal:  Nat Med       Date:  2013-02       Impact factor: 53.440

6.  Enhanced antibody responses to Plasmodium falciparum Pfs28 induced in mice by conjugation to ExoProtein A of Pseudomonas aeruginosa with an improved procedure.

Authors:  Feng Qian; Joan A Aebig; Karine Reiter; Emma Barnafo; Yanling Zhang; Richard L Shimp; Kelly M Rausch; David S Jones; Daming Zhu; Lynn Lambert; Gregory E D Mullen; David L Narum; Louis H Miller; Yimin Wu
Journal:  Microbes Infect       Date:  2008-12-27       Impact factor: 2.700

7.  Apical surface expression of aspartic protease Plasmepsin 4, a potential transmission-blocking target of the plasmodium ookinete.

Authors:  Fengwu Li; Kailash P Patra; Charles A Yowell; John B Dame; Karen Chin; Joseph M Vinetz
Journal:  J Biol Chem       Date:  2010-01-07       Impact factor: 5.157

8.  Population biology of malaria within the mosquito: density-dependent processes and potential implications for transmission-blocking interventions.

Authors:  Thomas S Churcher; Emma J Dawes; Robert E Sinden; George K Christophides; Jacob C Koella; María-Gloria Basáñez
Journal:  Malar J       Date:  2010-11-04       Impact factor: 2.979

9.  No evidence for positive selection at two potential targets for malaria transmission-blocking vaccines in Anopheles gambiae s.s.

Authors:  Jacob E Crawford; Susan M Rottschaefer; Boubacar Coulibaly; Madjou Sacko; Oumou Niaré; Michelle M Riehle; Sékou F Traore; Kenneth D Vernick; Brian P Lazzaro
Journal:  Infect Genet Evol       Date:  2013-01-26       Impact factor: 3.342

10.  Analysis of von Willebrand factor A domain-related protein (WARP) polymorphism in temperate and tropical Plasmodium vivax field isolates.

Authors:  Saber Gholizadeh; Navid Dinparast Djadid; Hamid Reza Basseri; Sedigheh Zakeri; Hossein Ladoni
Journal:  Malar J       Date:  2009-06-23       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.